FDA Approves Pancreatic Cancer Pill That Doubles Survival

The FDA just fast-tracked a new oral treatment, Onivyde, for metastatic pancreatic cancer, a particularly aggressive form. The pill, from Ipsen Biopharmaceuticals, nearly doubles patient survival from roughly 5.9 months to 11.1 months when used in combination with other drugs. It’s a huge step for a disease that's been historically tough to treat.